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Human papillomavirus (HPV) vaccination programmes in the UK were established in 2008, and 
targeted females aged 12-13 years. This decision was based on recommendations from the Joint 
Committee for Vaccination and Immunisation (JCVI), after assessing the available evidence for the 
impact and cost effectiveness of HPV vaccination programmes. The theory was that reducing HPV 
rates in females would result in lower infection rates in males of a similar age. This herd immunity 
did not extend to men-who-have-sex-with-men (MSM) or heterosexual men having sex abroad. 
Public Health England undertook a trial of a targeted HPV vaccination programme for MSM in 
2016/17. The 12-month pilot involved MSM up to 45 years of age being offered Gardasil 4, a 
quadrivalent HPV vaccine, through genitourinary medicine (GUM) and HIV clinics across England. 
GPs were not included in the pilot as there was insufficient evidence of acceptability and effective 
delivery. The pilot was reported as a success, and PHE has recommended rolling out this 
programme across England(1). The JCVI issued an interim statement regarding extending HPV 
immunisation to adolescent males in July 2017, again concluding that there was insufficient 
evidence for benefit in males(2). However, after strong responses through stakeholder 
consultations, continued pressure from lobby groups such as HPV Action (www.hpvaction.org), 
and further analysis of the latest research, the JCVI recently recommended extending the HPV 
vaccination programme to adolescent males on July 18 2018(3). 
 
Human papillomavirus 
HPV is a major cause of infection-related cancers. It is associated with cervical, anal, 
oropharyngeal, penile, vulval and vaginal cancers, as well as anogential warts. HPV subtypes 16 
and 18 are the most prevalent forms, and they are also the subtypes most strongly associated 
with HPV-related cancers(4). Risk factors for HPV infection include age, number of sexual partners, 
co-infection with other sexually transmitted diseases, condom use, anal sex, immunosuppression, 
and cigarette smoking(5). HPV infection rates in women and heterosexual men of corresponding 
age in England and Wales are expected to fall following the introduction of a HPV vaccination 
programme for girls in 2008. 
 
The incidence of HPV-related cancers that affect males, such as anal, penile and oropharyngeal 
cancers, are on the rise. Rates of anal squamous cell carcinoma in England between 1990-2010 in 
men increased from 0.43 per 100,000 population to 0.73 per 100,000, a rise of 69%(6). HIV-
negative MSM have a four-fold higher risk of anal cancer when compared to HIV-negative 
heterosexual men and women; HIV-positive men have an up to 80-fold higher risk(7). In the US, 
men were found to have rates of oropharyngeal cancer of 7.6 per 100,00, four times higher than 
women (1.7 per 100,000) between 2008 -2012. Anogenital warts are caused by a number of HPV 
strains, not just those covered by currently available HPV vaccines. The total number of patients 
with genital warts in England from 1971-2001 increased eight-fold, presumed to be mainly due to 
changing sexual practices(4), although there has been a reduction in incidence in recent years. 
 
HPV vaccination programmes 
All nations of the UK currently employ HPV vaccine programmes for adolescent females age 12-13, 
using the quadrivalent HPV vaccine. Scotland also offers HPV vaccination for MSM through sexual 
health and HIV clinics. 
 Forty-two sexual health and HIV clinics in England were included in the pilot programme of 
vaccinating MSM, with 18,875 MSM attending in that time. 8,580 (45.5%) of MSM attending the 
clinics in the pilot accepted at least one dose of the vaccine. The vast majority of MSM who 
completed a feedback survey during their clinic visit (7821/9584 [94.6%]) stated they would prefer 
to receive subsequent vaccine doses at the same clinic. 677 (7.2%) would have preferred to 
receive subsequent doses at their GP practice. Only 636 (3.4%) declined the vaccine, meaning the 
vaccination status of over half of the participants (9659 [51.2%]) in the pilot is unknown. 
 
Internationally, various approaches have been adopted to protect those at high-risk of HPV-
related diseases. Australia and the Canadian province of Quebec offer gender-neutral HPV 
vaccination programmes. Targeted HPV vaccination for MSM under the age of 26 years is available 
in the US and Ireland. Denmark recently announced a time-limited HPV vaccination of MSM via 
their GPs. There is on-going debate about the cost effectiveness of gender-neutral versus female-
only HPV vaccination, and the efficacy of relying on herd immunity to protect males from HPV 
infection. Ethical and equality concerns about denying HPV vaccination to an individual on the 
basis of their gender have also been raised(3). 
 
Delivering an effective HPV vaccination programme 
Following the JCVI’s recommendation to extend HPV vaccination to males, the Welsh and Scottish 
governments confirmed they would be implementing the JCVI’s advice in offering HPV vaccination 
to adolescent males as well as females. At the time of writing this editorial, no official response 
from the English government or the Northern Ireland assembly had been made, and there has 
been no discussion of any form of catch-up vaccination programme for older males. 
 
HPV vaccination uptake amongst adolescent females in the UK is currently above 80%, with 83.1% 
of 12-13 year-old females completing a two-dose schedule in 2016/17. This rate has slightly 
dropped from 86.7% in 2013/14(8). Coverage in the UK remains high despite a significant drop in 
recent years in coverage in some European countries, such as Denmark and the Republic of 
Ireland. UK nations that follow the JCVI recommendation and offer HPV vaccination to adolescent 
males will need to clearly inform parents of the effects of HPV vaccination for their sons to try to 
ensure uptake is high enough for the vaccination programme to be effective. 
 
The question needs to be asked whether rolling out a targeted HPV vaccination programme for 
MSM through sexual health clinics in England alongside a gender-neutral programme for 
adolescent males and females is an effective use of public health resources. The pilot failed to 
achieve 50% coverage for the first dose of the HPV vaccine for MSM, and even lower coverage for 
subsequent doses. The evidence is clear that HPV vaccination is most efficacious when delivered 
prior to exposure to the virus(9). It is also known that MSM are often reluctant to declare their 
sexual orientation to healthcare professionals and MSM seldom attend healthcare services prior 
to sexual debut(10), creating doubts about the effectiveness of a targeted programme delivered 
via sexual health clinics. Expanding access for a targeted programme to include GPs could boost 
coverage amongst MSM, however GPs are less confident in identifying young MSM who may 
benefit compared to sexual healthcare professionals(11). 
 
The International Papillomavirus Society recently released a statement calling for ‘the policy, the 
resources, political will and the public’s determination’ to move towards eliminating HPV as a 
public health problem(12). The JCVI recommendation to extend HPV vaccination to males in the 
UK is the first step in changing policy. Public support for HPV vaccination for males has been 
strong. Now the political will and proper resources are needed to make gender-neutral HPV 
vaccination a reality and reduce the incidence of HPV-related diseases for future generations in 
the UK. 
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